¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¾Æ»êº´¿ø Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À° : 2023-06-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

¼­¿ï¾Æ»êº´¿ø Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À° : 2023-06-10
±³À°ÀÏÀÚ : 2023-06-10
±³À°Àå¼Ò : ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç

±³À°ÁÖÁ¦ : Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À°

ÁÖÃÖ±â°ü : ¼­¿ï¾Æ»êº´¿ø
´ã´çÀÚ : ¿ì¹Ì°æ
¿¬¶ôó : 02-3010-4560  

À̸ÞÀÏ : rainmk@rainmk@amc.seoul.kr

±³À°Á¾·ù : º´¸®°ú

Âü¼®¿¹»óÀÎ : 90¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í "1. Àü°øÀÇ/±ºÀÇ°ü/¿¬±¸¿ø   »çÀüÁ¢¼ö 20,000¿ø ÇöÀåÁ¢¼ö 30,000¿ø

2. Àü¹®ÀÇ /¹Ú»ç  »çÀüÁ¢¼ö 40,000¿ø  ÇöÀåÁ¢¼ö 50,000¿ø"

±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 10:00~10:40 Clinical Application of ctDNA in Medical Oncology ±è»óÀ§(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 10:40~11:40 Strategic development of anti-cancer immunotherapy using single cell RNA sequencin ÀÌÇý¿Á(°¡Å縯´ëÇб³)

½Ä»ç 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 11:40~13:10 Á¡½É ()

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 13:10~13:40 Liquid Biopsy based Clinical NGS at ASAN Pathology õ¼º¹Î(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 13:40~14:10 The age of whole genome sequencing: ready yet in clinics? ¼ºÃ¢¿Á(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 14:10~14:40 Longitudinal NGS analysis and early drug development À±½Å±³(¼­¿ï¾Æ»êº´¿ø)

ÈÞ½Ä 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 14:40~15:00 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 15:00~15:30 Digging out useful information through NGS in cancer of unknown primary setting ±èÁöÈÆ(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 15:30~16:00 Clinical significance of concurrent genomic alterations in EGFR-mutant lung adenocarcinoma ȲÈñ»ó(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 16:00~16:30 Detection and interpretation of non-canonical fusions ¼ÛÀÎÇý(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 10ÀÏ ¾Æ»ê»ý¸í°úÇבּ¸¿ø ¼Ò°­´ç 16:30~17:00 Efforts to utilize clinical NGS data in AMC ±è´öÈÆ(¼­¿ï¾Æ»êº´¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¾Æ»êº´¿ø Á¦ 6Â÷ ºÐÀÚº´¸® ¿¬¼ö±³À° : 2023-06-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³âµµ Á¦21ȸ ¼­¿ï½Ã ³²¼­ 7°³±¸ ÀÇ»çȸ ÇÕµ¿ Çмú´ëȸ : 2023-06-10
´ÙÀ½±Û Á¦7ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2023-06-10
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20988 ¼­¿ï 2024 Á¦ 13ȸ ´ëÇѺñ´¢»ý½Ä±âÅëÇÕ±â´ÉÀÇÇבּ¸È¸ Çмú´ëȸ : 2024-06-22 0 7 2024-06-14
20987 Ãæ³² 2024³â ´ëÇÑ°í°üÀýÇÐȸ Áø·áÁöħ ½ÉÆ÷Áö¿ò : 2024-06-22 0 7 2024-06-14
20986 ±¤ÁÖ Á¦24ȸ ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ È£³²Áöȸ Á¤±âÇмú´ëȸ : 2024-06-22 0 8 2024-06-14
20985 °æ±â ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Annual Academy for young oncologists(2ÀÏÂ÷) : 2024-06-22 0 6 2024-06-14
20984 °æºÏ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦43Â÷ ÇÏ°è±¹Á¦Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-22 0 3 2024-06-14
20983 °æ³² 2024 ÁøÁÖ½ÃÀÇ»çȸ »ó¹Ý±â Àǻ翬¼ö±³À° : 2024-06-22 0 3 2024-06-14
20982 °æ±â °¡Å縯´ëÇб³ÀÇÁ¤ºÎ¼º¸ðº´¿ø Á¦ 8Â÷ °æ±âºÏºÎ °³¿øÀǸ¦ À§ÇÑ Çмú´ëȸ : 2024-06-22 0 4 2024-06-14
20981 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ½ÉÆ÷Áö¾ö : 2024-06-22 0 2 2024-06-14
20980 ¼­¿ï ´ëÇÑÈĵÎÀ½¼º¾ð¾îÀÇÇÐȸ 11ȸ °ø¿¬¹ß¼º ½ÉÆ÷Áö¾ö : 2024-06-22 0 4 2024-06-14
20979 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇѳëÀÎÀçÈ°ÀÇÇÐȸ ³ëÀÎÀçÈ°Àü¹®°¡ ½ÉÈ­°úÁ¤ : 2024-06-22 0 2 2024-06-14
20978 ÀüºÏ Á¦75Â÷ Çѱ¹ÃéÀå¿Ü°úÇÐȸ Çмú´ëȸ : 2024-06-22 0 3 2024-06-14
20977 Á¦ÁÖ ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ The 18th Annual Summer Conference on Endovascular Neurosurgical Therapy (ASCENT 2024) 2ÀÏÂ÷ : 2024-06-22 0 2 2024-06-14
20976 ±¤ÁÖ 2024³â »ó¹Ý±â ±¤ÁÖ±¤¿ª½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-22 0 1 2024-06-14
20975 ¼­¿ï 2024³â ´ëÇÑÀÇ·áÁ¤º¸ÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-21 0 2 2024-06-14
20974 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2024 SNUH Rare Disease Workshop : 2024-06-21 0 1 2024-06-14
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷